Radium Ra 223 Dichloride

RADIATION11 trials

Sponsors

University of Utah, Carolina Research Professionals, LLC, Sidney Kimmel Cancer Center at Thomas Jefferson University, National Cancer Institute (NCI), University of Southern California

Conditions

Advanced Renal Cell CarcinomaAnatomic Stage IV Breast Cancer AJCC v8Castration-Resistant Prostate CarcinomaChromophobe Renal Cell CarcinomaClear Cell Renal Cell CarcinomaCollecting Duct CarcinomaHormone-refractory Prostate CancerKidney Medullary Carcinoma

Phase 1

Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad)

CompletedNCT03076203

Sidney Kimmel Cancer Center at Thomas Jefferson UniversityHormone-refractory Prostate Cancer, Prostate Carcinoma Metastatic to the Bone, Stage IV Prostate Adenocarcinoma

Start: 2017-09-22End: 2022-11-07Updated: 2025-04-29

Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced Prostate Cancer With Bone Metastasis

Active, not recruitingNCT03317392

National Cancer Institute (NCI)Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8

Start: 2019-02-04End: 2027-02-16Updated: 2026-02-19

Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy

RecruitingNCT04071236

National Cancer Institute (NCI)Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lymph Nodes +1

Start: 2020-10-14End: 2026-04-30Target: 90Updated: 2026-04-03

Phase 2

Radium Ra 223 With Enzalutamide Compared to Enzalutamide Alone in Men With Metastatic Castration Refractory Prostate Cancer

CompletedNCT02199197

University of UtahProstate Cancer

Start: 2014-06-25End: 2019-10-03Updated: 2020-10-30

Open Label Phase Two Study of Enzalutamide With Concurrent Administration of Radium Ra 223 Dichloride in Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Symptomatic Bone Metastasis

CompletedNCT02507570

Carolina Research Professionals, LLCProstate Carcinoma Metastatic to the Bone

Start: 2015-09-23End: 2019-01-18Updated: 2019-03-19

Radium-223 and Radiotherapy in Hormone-Naïve Men With Oligometastatic Prostate Cancer to Bone

CompletedNCT03304418

University of UtahProstate Cancer Metastatic to Bone

Start: 2018-02-27End: 2023-08-31Updated: 2025-04-30

Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer

Active, not recruitingNCT03344211

University of Southern CaliforniaCastration-Resistant Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone, Stage IV Prostate Cancer

Start: 2018-11-21End: 2027-11-21Updated: 2026-02-27

Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer

Active, not recruitingNCT03361735

City of Hope Medical CenterProstate Adenocarcinoma

Start: 2018-08-29End: 2026-02-04Updated: 2025-05-02

Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study

Active, not recruitingNCT04071223

National Cancer Institute (NCI)Advanced Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma +6

Start: 2020-07-29End: 2026-10-01Target: 134Updated: 2026-04-03

Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones

Active, not recruitingNCT04090398

National Cancer Institute (NCI)Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma, Metastatic Malignant Neoplasm in the Bone

Start: 2020-08-04End: 2026-06-30Target: 70Updated: 2026-04-03

Unknown Phase

Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer

RecruitingNCT04489719

University of WashingtonCastration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Prostate Carcinoma +1

Start: 2021-04-16End: 2029-08-01Target: 48Updated: 2026-02-17

Related Papers

A multicenter, randomized, phase 2, investigator-initiated ETCTN trial of olaparib + radium-223 vs. radium-223 in men with castration-resistant prostate cancer (CRPC) with bone metastases (BM) (COMRADE): Initial efficacy and biomarker analysis.

Journal of Clinical Oncology2025-05-284 citations

The impact of DNA repair genetic alterations identified by circulating tumor DNA on sensitivity to radium-223 in bone metastatic, castration-resistant prostate cancer.

Journal of Clinical Oncology2025-05-28

A phase l and randomized phase ll trial of radium-223 dichloride, peposertib, and avelumab in advanced metastatic castrate-resistant prostate cancer (mCRPC): Phase l results.

Journal of Clinical Oncology2025-05-28

A randomized trial of radium-223 dichloride and cabozantinib in patients with advanced renal cell carcinoma (RCC) with osseous metastases (RADICAL/Alliance A031801).

Journal of Clinical Oncology2025-05-28

Mature results of a phase 2 pilot study of radium-223 and radiotherapy in untreated hormone-naïve men with oligometastatic prostate cancer to bone.

Journal of Clinical Oncology2024-01-291 citations

A Phase Ib Study of the DNA-PK Inhibitor Peposertib Combined with Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer

Clinical Cancer Research2023-12-0528 citations

A phase 1/2 study of combination olaparib and radium-223 in men with metastatic castration-resistant prostate cancer with bone metastases (COMRADE): A trial in progress.

Journal of Clinical Oncology2023-06-012 citations

A phase II randomized trial of metastasis-directed therapy with alpha emitter radium-223 in men with oligometastatic castration-resistant prostate cancer (MEDAL).

2023-03-064 citations

Difficulties in Defining Oligometastatic Prostate Cancer: Implications for Clinical Trial Accrual and Community Practice Adoption of Metastasis-Directed Therapy Approaches

Journal of Clinical Medicine2023-03-031 citations

Initial results of a phase 2 pilot study of radium-223 and radiotherapy in untreated hormone-naïve men with oligometastatic prostate cancer to bone.

Journal of Clinical Oncology2023-02-20

AlphaBet: Combination of Radium-223 and [177Lu]Lu-PSMA-I&T in men with metastatic castration-resistant prostate cancer (clinical trial protocol)

Frontiers in Medicine2022-11-1840 citations

561 Immune activation and clinical response from enzalutamide (enza) alone or with radium223 (Ra223) in metastatic castration-resistant prostate cancer (mCRPC)

Regular and Young Investigator Award Abstracts2022-11-01

Updated biomarker results from a phase 1/2 study of olaparib and radium-223 in men with metastatic castration-resistant prostate cancer (mCRPC) with bone metastases (COMRADE).

Journal of Clinical Oncology2022-02-162 citations

A randomized trial of radium-223 (Ra-223) dichloride and cabozantinib in patients (pts) with advanced renal cell carcinoma (RCC) with bone metastases (RADICAL/Alliance A031801).

Journal of Clinical Oncology2021-05-207 citations

A phase 1/2 study of olaparib and radium-223 in men with metastatic castration-resistant prostate cancer (mCRPC) with bone metastases (COMRADE): Results of the phase 1 study.

Journal of Clinical Oncology2021-05-207 citations

Biomarker analysis of phase (Ph) IB trial of radium-223 (Rad) and niraparib (Nira) in patients (Pts) with metastatic castrate-resistant prostate cancer (mCRPC) (NiraRad).

Journal of Clinical Oncology2021-05-202 citations

Besserer Outcome unter Radium-223 plus Enzalutamid versus Enzalutamid allein

Onkologische Welt2021-04-01

A phase I/II study of combination olaparib and radium-223 in men with metastatic castration-resistant prostate cancer with bone metastases (COMRADE): A trial in progress.

Journal of Clinical Oncology2021-02-209 citations

Randomized phase II trial of radium-223 (RA) plus enzalutamide (EZ) versus EZ alone in metastatic castration-refractory prostate cancer (mCRPC): Final efficacy and safety results.

Journal of Clinical Oncology2021-02-201 citations

Radium-223 (Rad) and niraparib (Nira) treatment (tx) in castrate-resistant prostate cancer (CRPC) patients (pts) with and without prior chemotherapy (chemo).

Journal of Clinical Oncology2020-05-209 citations

5 more papers not shown